News

23

Mar, 2022

Borrowing information across patient subgroups in clinical trials

Tags:

An article by investigators within the ODYSSEY trial has been published as Open Access into BMC Medical Research Methodology. The investigators aimed to evaluate a treatment effect in a pre-defined subgroup of interest while borrowing information from a separate patient subgroup, using a Bayesian analysis. A Bayesian analysis enables evidence from data to be combined with prior information from an external sample. Phase III clinical trials demonstrate whether or not medical intervention is effective and safe in a specific population. For various reasons, investigators may choose to evaluate effectiveness and safety […]

READ MORE

23

Mar, 2022

Dolutegravir dosing for children with HIV weighing less than 20 kg

Tags: ,

The results of an ODYSSEY pharmacokinetic sub-study investigating dolutegravir (DTG) based antiretroviral (ARV) treatments for children weighing 3 to less than 20kg have recently been published in The Lancet HIV as an Open Access article. DTG has been available for treating HIV in adults globally for many years with paediatric formulations only developed in recent years. Very little pharmacokinetic data were available in young children when the ODYSSEY trial was opened to young children. With this in mind, the team nested a sub-study to evaluate pharmacokinetics and safety and confirm the optimal […]

READ MORE

15

Mar, 2022

What is PentaTr@ining

Tags:

PentaTr@ining (formerly ‘Tr@inforPedHIV’) is a groundbreaking training platform for healthcare professionals caring for children, adolescents and pregnant women living with infectious diseases – with a particular focus on HIV and congenital infections. Unique at its inception in 2005, it was established in the framework of the partnership between Penta and the European Society for Paediatric Infectious Diseases (ESPID). The course was initially designed to address topics related to the treatment of children with HIV/AIDS in Western and Eastern Europe. However, the great success of those first experiences has led Penta […]

READ MORE

14

Mar, 2022

WHO Paediatric ARV dosing dashboard

Tags: , ,

The WHO have developed a Paediatric ARV dosing dashboard which aims to support health care workers, researchers and policy makers in decisions around ARV dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years old, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who want to investigate various ARV dosages and calculate the expected drug exposure in children relative to adult targets after administration of various doses. […]

READ MORE

2

Mar, 2022

Penta stands with the Ukrainian people and those in Russia who are opposing war

 

On 24 February 2022, the Russian government deployed its military into its neighboring country, Ukraine. In these dark hours, we are tormented by the thought of our Ukrainian friends, the fate of women, children and healthcare workers trapped in a senseless conflict. We could have never imagined that our friends, Russians, Ukrainians and all those living within the Ukrainian border, who are building a brighter future for child health with us, would find themselves divided by a frontier of gunfire. In 30 years of research to improve children’s health, we […]

READ MORE

1

Mar, 2022

Gap-f launches strategy plan!

Tags: ,

On March 1, 2022, the GAP-f network held a virtual event to launch its ambitious three-year strategy, spanning from 2022-2024. Through this event, the network solidified the WHO’s commitment to advancing health outcomes for children globally. GAP-f's three-year strategy (2022–2024) builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. The initial Phase I strategy focused on HIV, tuberculosis (TB) and hepatitis C products, and this new three-year strategy builds on the work undertaken in these disease areas, targeting additional therapeutic [...]
READ MORE

16

Feb, 2022

VERDI General Assembly Meeting

 

On 26-28 January the VERDI General Assembly Meeting took place – an exciting 3-day online event bringing together experts in infectious diseases from the EU and beyond. The aim was to share our workplan, identify research areas of interest for the Consortium and prioritize crucial scientific questions about the epidemiology, transmission, disease progression and treatment of variants of SARS-CoV-2 among children and pregnant women, which the Consortium will collaboratively seek to answer. There are several issues concerning the evolution of the pandemic that have emerged over the last months, many […]

READ MORE

15

Feb, 2022

Ecraid begins its fight against infectious diseases 

Tags:

New foundation: The European Clinical Research Alliance for Infectious Diseases has begun   Utrecht, Tuesday 15 February 2022 – In January 2022, Ecraid became a legal entity and is now fully operational to advance knowledge in the field of infectious diseases. This is Ecraid’s initial step as it evolves into a self-sustaining, not-for-profit organisation conducting clinical research for both public and private sponsors. The expertise required to clinically evaluate new diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions is not confined to a single institute or country. In fact, [...]
READ MORE

11

Feb, 2022

Closer to micro-elimination of HCV in Russian adolescents and children

Tags: ,

The REACH Consortium has just published the results of a multi-centre survey, aimed at assessing the uptake of Direct-acting antivirals (DAAs) for the treatment of HCV in children and adolescents living in Russia. The article is available as Open access in the Journal of Virus Eradication. DAAs, new drugs used to treat chronic HCV, have demonstrated high rates of cure with minimal toxicity when compared to interferon-based regimens. They have been available for adults in Russia since 2015 and in 2019 they were approved for treatment of HCV in adolescents […]

READ MORE

11

Feb, 2022

Registration now open! PentaTr@ining 2022: HIV & other Congenital Infections

Tags:

We are delighted to announce that registrations are now open for our interactive training course ‘PentaTr@ining 2022: HIV & other Congenital Infections‘. Building on the remarkable success of the previous online course in 2020/21, we have adapted our training content to deliver a cutting-edge training programme centered around updates in the management of paediatric HIV and a variety of different congenital infections. We have listened to participant feedback and carefully tailored the course to address the key issues that currently face paediatric infectious disease healthcare professionals and students. The course […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities